info1775741 sep. 20211 minutenCSO shift at BunyaVaxPer 31 Aug 2021 Jeroen Kortekaas resigned as CSO of BunyaVax. He has been CSO since September 2017. Jeroen will continue his career as...
Jeroen Kortekaas15 sep. 20201 minutenSafety and efficacy of four-segmented Rift Valley fever virus in young sheep, goats and cattlePlease find here our latest paper on the safety and efficacy of our veterinary Rift Valley fever vaccine: https://www.ncbi.nlm.nih.gov/pm...
info17757426 feb. 20201 minutenCEO shift at BunyaVaxPer 31 December 2019, Jochem Bossenbroek resigns as CEO of BunyaVax. He has been CEO since September 2017. Carine Punt has been appointed...
info17757410 okt. 20191 minutenBunyaVax CEO on stage at Animal AgTech Innovation SummitOn 29-30 September, the first Animal AgTech Innovation Summit was held in Amsterdam. The summit brought together 200 international...
info17757410 jul. 20194 minutenBunyaVax provides technology to develop a human Rift Valley Fever vaccine in a $12.5 million projectBunyaVax provides technology to develop a human Rift Valley Fever vaccine in a $12.5 million project financed by CEPI BunyaVax is...
info17757417 jan. 20191 minutenJochem Bossenbroek speaker at Investment Trends In Animal HealthOn the 17th of January 2019, Jochem will be one of the speakers at the live webinar Investment Trends in Animal Health. The webinar is...
info17757428 sep. 20181 minutenBunyaVax featured in 10 Dutch Breakthrough Technologies for 2018On Thursday 27 September StartupDelta announced their overview of 10 Dutch Breakthrough Technologies for 2018. BunyaVax made it to the...
info17757422 aug. 20181 minutenJochem Bossenbroek invited to speak at the World Agri-Tech Innovation SummitJochem Bossenbroek, CEO of BunyaVax, has accepted the invitation to join a panel discussion at the World Agri-Tech Innovation Summit. The...
info1775747 aug. 20181 minutenJeroen Kortekaas to present at the Immuno Valley Annual ConferenceJeroen Kortekaas, CSO of BunyaVax, is invited as session speaker at the Immuno Valley Annual Conference 2018. The event will take place...
info17757413 jun. 20181 minutenBunyaVax featured in Wageningen WorldThe journal Wageningen World has published an article about BunyaVax in the second edition of 2018: "Vaccines within months instead of...
info1775746 apr. 20181 minutenPrestigious SME Instrument funding for BunyaVaxBunyaVax receives 50.000 euro from the European Commission (EC). The funding proposal of BunyaVax was selected out of hundreds of...
info17757428 feb. 20181 minutenBunyaVax wins innovation award in LondonLast week BunyaVax has won the 2018 Innovation Showcase Award at Animal Health Investment Europe. The event, organized by Kisaco...
info17757410 jan. 20181 minutenBunyaVax to present at Animal Health Investment SummitBunyaVax will present at the Animal Health Investment Summit in Londen that will take place on 20-21 Februari 2018. BunyaVax is one of...
info17757410 jan. 20181 minutenBunyaVax receives 40k Take-off grantBunyaVax has been awarded €40k under the NWO Take-off programme. The grant allows BunyaVax to determine the route to market for its swine...
info1775741 sep. 20171 minutenJochem Bossenbroek appointed as CEOBunyaVax has appointed Jochem Bossenbroek MSc. MBA as CEO of the company. Jochem has extensive experience in the biotech sector, gained...
info17757426 jul. 20172 minutenJeroen Kortekaas and Paul Wichgers Schreur announce vision for BunyaVaxProf. Jeroen Kortekaas PhD, CSO of BunyaVax, and Paul Wichgers Schreur PhD, COO of the company, share their vision on the future of...
info1775743 jul. 20171 minutenOfficial launch of BunyaVax B.V.Today, the biotech company BunyaVax B.V. was officially launched. Goal of the company is to commercialize novel proprietary vaccine...